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The present study evaluated the acute effect of the intraperitoneal (ip)
administration of a whey protein hydrolysate (WPH) on systolic
arterial blood pressure (SBP) and renal sodium handling by conscious
spontaneously hypertensive rats (SHR). The ip administration of
WPH in a volume of 1 ml dose-dependently lowered the SBP in SHR
2 h after administration at doses of 0.5 g/kg (0.15 M NaCl: 188.5 ± 9.3
mmHg vs WPH: 176.6 ± 4.9 mmHg, N = 8, P = 0.001) and 1.0 g/kg
(0.15 M NaCl: 188.5 ± 9.3 mmHg vs WPH: 163.8 ± 5.9 mmHg, N =
8, P = 0.0018). Creatinine clearance decreased significantly (P =
0.0084) in the WPH-treated group (326 ± 67 µL min-1 100 g body
weight-1) compared to 0.15 M NaCl-treated (890 ± 26 µL min-1 100 g
body weight-1) and captopril-treated (903 ± 72 µL min-1 100 g body
weight-1) rats. The ip administration of 1.0 g WPH/kg also decreased
fractional sodium excretion to 0.021 ± 0.019% compared to 0.126 ±
0.041 and 0.66 ± 0.015% in 0.15 M NaCl and captopril-treated rats,
respectively (P = 0.033). Similarly, the fractional potassium excretion
in WPH-treated rats (0.25 ± 0.05%) was significantly lower (P =
0.0063) than in control (0.91 ± 0.15%) and captopril-treated rats (1.24
± 0.30%), respectively. The present study shows a decreased SBP in
SHR after the administration of WPH associated with a rise in tubule
sodium reabsorption despite an angiotensin I-converting enzyme
(ACE)-inhibiting in vitro activity (IC50 = 0.68 mg/mL). The present
findings suggest a pathway involving ACE inhibition but measure-











Research supported by CNPq (No.
500868/91-3), PRONEX (No. 0134/97),
CAPES, and FAPESP (No. 00/12216-8).
Received January 30, 2004
Accepted August 11, 2005
Key words
• Arterial blood pressure
• Hydrolysis
• Renal function
• Urinary sodium excretion
• Whey protein isolate
1818
Braz J Med Biol Res 38(12) 2005
E.L. Costa et al.
Introduction
Peptides derived from food proteins can
regulate physiological functions in the di-
gestive, neural and cardiovascular systems
(1-3). A functional food can be defined as a
dietary ingredient that affects its host in a
targeted manner so as to exert positive ef-
fects that may eventually justify certain health
claims. The term functional food encom-
passes a very broad range of products from
foods generated around a particular func-
tional ingredient (e.g., stanol-enriched mar-
garine) to staple, everyday foods enriched
with a nutrient not usually present to any
great extent (e.g., folic acid enriched bread
or breakfast cereals). Peptides derived from
soybean and pork proteins can suppress the
increase in serum cholesterol after a meal
(4,5), while those derived from casein hy-
drolysates treated with pepsin promote cal-
cium absorption and are used as functional
foods, i.e., they contain ingredients that have
health-promoting properties that extend be-
yond their immediate nutritional value. Pep-
tides with hypotensive activity have been
identified in hydrolysates of gelatin, casein,
maize endosperm protein, and fish muscle
(6-9), and are believed to be useful as func-
tional dietary ingredients for hypertensive
patients. This activity is attributable mainly
to the inhibition of angiotensin-I-converting
enzyme (ACE), which plays a prominent
role in the regulation of arterial blood pres-
sure by converting the inactive decapeptide
angiotensin I to a strong vasoconstrictor oc-
tapeptide, angiotensin II, while at the same
time inactivating the vasodilator and natri-
uretic nonapeptide, bradykinin (10,11).
Milk proteins are precursors of peptides
with various biological activities, including
opioid activity and immunomodulatory and
antihypertensive actions (12). The antihy-
pertensive effect of these peptides has also
been related to the inhibition of ACE (13),
and has been studied in spontaneously hy-
pertensive rats (SHR) and humans (14,15).
These biologically active peptides are re-
leased from milk proteins by enzymatic hy-
drolysis during gastrointestinal digestion,
milk fermentation (16) or hydrolysis in vi-
tro. The most common way to produce
bioactive peptides is to release them by lim-
ited hydrolysis using pancreatic enzymes,
mainly trypsin. However, other enzymes and
combinations of proteases have been used to
generate bioactive peptides. Several studies
have used alcalase to obtain antihyperten-
sive hydrolysates from many protein sources
(17-19). This enzyme is an industrial alka-
line protease that is very stable in organic
solvents and serves as a catalyst for the
resolution of N-protected amino acids in
aqueous solution and organic solvents, and
is used to prepare optically pure peptides.
For many years, dietary interventions as
a non-pharmacological approach for treat-
ing hypertension have focused on the intake
of electrolytes. However, according to Mar-
tin (20), manipulation of the dietary protein
content could also be useful in the non-
pharmacological treatment of hypertension.
However, to the best of our knowledge, no
study has investigated the hypotensive and
renal effects of protein hydrolysates. In the
present study, the in vitro ACE-inhibiting
activity of a whey protein hydrolysate (WPH)
and its effect on blood pressure, renal func-
tion and renal handling of sodium were in-
vestigated in conscious SHR.
Material and Methods
The experiments were conducted on male
SHR (270-300 g) that were allowed free
access to tap water and standard rat labora-
tory chow (Purina rat chow: Na+ content:
135 ± 3 µEq/g; K+ content: 293 ± 5 µEq/g).
To evaluate the effect of the ip administra-
tion of WPH on systolic blood pressure (SBP)
and renal function, non-anesthetized rats
were randomly assigned to one of three
groups: 1) rats receiving vehicle solution ip
(0.15 M NaCl, N = 6), 2) captopril-treated
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rats (captopril, 10 mg/kg, ip, N = 6), and 3)
WPH-treated rats (WPH, at 1.0 g/kg, ip, N =
8) in a volume of 1 mL. The general guide-
lines established by the Brazilian College
for Animal Experimentation (COBEA) were
followed throughout the study. The doses of
WPH used during the renal function tests
were chosen after a preliminary dose-re-
sponse study to assess the effects of WPH on
SBP in a separate group of rats.
Experimental design
To assess the effect of the dose of WPH
on SBP compared to control (0.15 M NaCl)
and captopril administration, the rats received
non-cumulative ip injections in a volume of
1 mL containing different doses of WPH
(0.25, 0.5, 0.75, and 1.0 g/kg). The SBP was
measured 2 h later in conscious, restrained
rats (N = 8 for each dose or experimental
group) by a tail-cuff method using an
electrosphygmomanometer (Narco Bio-Sys-
tems, Austin, TX, USA). This indirect ap-
proach allows repeated measurements and
yields values with a close correlation (corre-
lation coefficient = 0.975) to those obtained
by direct intra-arterial recordings (21).
For the renal function studies, the rats
were weighed and housed individually in
metabolic cages. These experiments were
done at the same time for each group. Four-
teen hours before the renal tests, 60 mmol
LiCl/100 g body weight was given by ga-
vage. After an overnight fast, each non-
anesthetized rat received tap water by ga-
vage (5% of body weight), followed by a
second load of the same volume 1 h later.
Twenty minutes after the second load, 0.15
M NaCl (control), 1.0 g WPH/kg body weight
or 10 mg captopril/kg body weight (the latter
two dissolved in 1 mL of 0.15 M NaCl) was
administered ip and spontaneously voided
urine was collected over a 2-h period. The
voided urine passed through a funnel in the
bottom of the cage into a graduated centri-
fuge tube. At the end of the experiment,
blood samples were drawn by cardiac punc-
ture, and urine and plasma samples were
taken for analysis.
Preparation of whey protein hydrolysate
Whey protein isolate (Davisco, Le Sueur,
MN, USA) was first denatured to 65ºC for
15 min under conditions described below.
The whey protein isolate suspension (10%
on a protein weight basis) was hydrolyzed
with alcalase (Novo Nordisk Biochem Inc.,
Franklinton, NC, USA) in a pH-Stat appara-
tus (Mettler Toledo, Columbus, OH, USA).
Hydrolysis was performed using an enzyme-
to-substrate protein ratio of 0.01 (v/w) at
60ºC. The suspension was maintained at pH
7.0 by the continuous addition of 1 N NH4OH
until 10% of the substrate was hydrolyzed.
At the end of the incubation, the solution
was heated to 90ºC for 10 min to stop en-
zyme activity and the hydrolysate was freeze-
dried. The extent of hydrolysis was meas-
ured on the basis of NaOH uptake.
Inhibitory effect of the whey protein
hydrolysate on ACE activity
The in vitro inhibition of ACE activity by
WPH (N = 24) was assessed by capillary
electrophoresis using a modification of the
method of Cushman and Cheung (22) previ-
ously described by Costa et al. (23). The
reaction was carried out by incubating ACE
(4 mU, 100 µL; Sigma, St. Louis, MO, USA)
and hippuryl-His-Leu (3.8 mM, 100 µL;
Sigma) in 100 mM sodium borate contain-
ing 300 mM NaCl, pH 8.3, for 30 min at
37ºC. Different concentrations of the hy-
drolysate dissolved in 50 µL borate buffer
were mixed with the ACE solution before
the addition of hippuryl-His-Leu to start the
reaction. The reaction was stopped by add-
ing acetonitrile (250 µL). The samples were
mixed and injected directly into the silica
capillary (52 cm x 75 µm ID) in the hydrody-
namic mode at a pressure of 50 mbar. The
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voltage applied was 10 kV for 30 min. The
hippuric acid released was detected at 228
nm using a diode array detector. The IC50
value was defined as the concentration of
hydrolysate (mg/mL) required to reduce the
hippuric acid peak by 50% (indicating 50%
inhibition of ACE).
Biochemical analyses
Plasma and urine sodium, potassium and
lithium concentration were measured by
flame photometry (Micronal, B262, São
Paulo, SP, Brazil), while the creatinine con-
centrations and WPH osmolarity were deter-
mined spectrophotometrically (Instruments
Laboratory, Genesys V, Lexington, MA,
USA) and with a wide-range osmometer
(Advanced Instruments Inc., Needham
Heights/Medkan Heights, MA, USA), re-
spectively.
Renal function calculations and statistics
The tail blood pressure measurements
and renal function results are reported as the
mean ± SEM per 100 g body weight. Renal
clearance was calculated using a standard
formula (C = UV/P) based on the plasma
creatinine and lithium levels. Creatinine
clearance (CCr) was used to estimate the
glomerular filtration rate and lithium clear-
ance (CLi+) was used to assess proximal
tubule sodium reabsorption. Fractional so-
dium (FENa+) and potassium (FEK+) excre-
tions were calculated as CNa+/CCr and CK+/
CCr, respectively, where CNa+ and CK+ are
the sodium and potassium clearances. The
fractional proximal (FEPNa+) and post-proxi-
mal (FEPPNa+) sodium excretions were cal-
culated as CLi+/CCr x 100 and CNa+/CLi+ x
100, respectively (24,25).
Data were analyzed statistically by the
unpaired Student t-test. The level of signifi-
cance was set at P < 0.05.
Results
In vitro inhibition of ACE activity by whey
protein hydrolysate
Figure 1 shows a chromatogram of the
ACE reaction mixture containing WPH at
several concentrations. Complete separation
of hippuric acid and hippuryl-His-Leu was
achieved with this method. The amount of
hippuric acid detected decreased as the con-
centration of WPH increased, indicating the
inhibition of ACE by WPH (Figure 1B-D).
The IC50 for WPH (0.68 mg/mL, N = 8)
indicated that the hydrolysate had moderate
ACE-inhibitory activity that was comparable
to that reported by Byun and Kim (18) (IC50
= 0.629 mg/mL) for a gelatin hydrolysate
obtained by digestion with alcalase, and to
that for milk hydrolyzed by a purified yeast
protease (IC50 = 0.42 mg/mL).
Hypotensive and renal effect of
intraperitoneally administered whey
protein hydrolysate on SHR
The experiments were performed by ip
injection of 0.15 M NaCl (control) or 215
mOsm/kg H2O protein hydrolysate solutions
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Figure 1. Capillary electrophoresis separation of the angiotensin I-converting enzyme
reaction mixture incubated without whey protein hydrolysate (WPH; A) and with WPH at
concentrations of 0.25 mg/mL (B), 0.5 mg/mL (C), and 1.0 mg/mL (D; N = 8 for each
concentration). HHL = hippuryl-His-Leu; HA = hippuric acid.
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and 0.1482 g/mL of 98.8% WPH (at 1.0 and
0.5 g/kg, respectively).
Figure 2A shows that the WPH signifi-
cantly and dose-dependently lowered the
SBP in SHR 2 h after the administration of
0.5 g WPH/kg (control: 188.5 ± 9.3 mmHg
vs WPH: 176.6 ± 4.9 mmHg, P = 0.001) and
1.0 g WPH/kg (control: 188.5 ± 9.3 mmHg
vs WPH: 163.8 ± 5.9 mmHg, P = 0.0018).
This decrease in SBP was similar to that
observed after treatment with captopril (ve-
hicle: 196.1 ± 3.3 mmHg vs captopril: 153.1
± 2.9 mmHg, P = 0.01). The maximum
percent decrease in SBP after administration
of the vehicle solution, captopril and WPH
was -2.2 ± 0.17, -21.3 ± 2.3 and -28.1 ±
3.6%, respectively.
Figure 2B-F shows the effect of the ve-
hicle solution, captopril and WPH on CCr
and renal Na+ and K+ handling in SHR. The
glomerular filtration rate estimated by CCr
decreased significantly in SHR treated with
1.0 g of WPH/kg body weight (326 ± 67 µL
min-1 100 g body weight-1) compared to
those receiving 0.15 M NaCl solution (890 ±
26 µL min-1 100 g body weight-1) and capto-
pril (903 ± 72 µL min-1 100 g body weight-1,
P = 0.0084). The ip administration of 1.0 g
WPH/kg body weight also decreased FENa+
to 0.021 ± 0.019% compared to 0.126 ±
0.041 and 0.66 ± 0.015% in vehicle- and
captopril-treated rats, respectively (P =
0.033). Similarly, the FEK+ in WPH-treated
rats (0.25 ± 0.05%) was significantly lower
(P = 0.0063) than in control (0.91 ± 0.15%)
and captopril-treated rats (1.24 ± 0.30%),
respectively.
The decrease in urinary sodium and po-
tassium excretion caused by WPH (1.0 g/kg
body weight, ip) was accompanied by a
significant decrease in proximal (control:
75.3 ± 15 vs WPH: 12.7 ± 5%) and post-
proximal (control: 0.43 ± 0.08 vs WPH: 0.16
± 0.076%) sodium excretion when com-
pared to 0.15 M NaCl- and captopril-treated
rats (FEPNa+: 141.3 ± 20%; FEPPNa+: 0.22
± 0.065%).
Discussion
Considerable resources have been de-
voted to studying the potential hypotensive
effects of milk protein-derived peptides in
SHR and hypertensive human volunteers
(26). We have, for the first time, studied the
effect of protein hydrolysates on renal func-
tion. The present study demonstrated that
the ip administration of WPH caused a
marked decrease in SBP and glomerular fil-
tration rate (Figures 1 and 2). This route of
administration was required by the peptide
nature of the agent being administered which
could not be oral. SBP was reduced 2 h after
the administration of WPH, and this de-
Figure 2. Effect of intraperitoneal administration of whey protein hydrolysate (WPH; 1.0 g/kg
body weight) on arterial blood pressure (vehicle: open circles; WPH: closed circles, A),
creatinine clearance (CCr, B), fractional excretion of sodium (FENa+, C), post-proximal
(FEPPNa+, D), and proximal (FEPNa+, E) fractional excretion of sodium, and fractional
excretion of potassium (FEK+, F). *P < 0.05 vs control (vehicle) group (Student t-test).
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crease was sustained for up to 4 h after
injection (data not shown). The WPH also
transiently but significantly decreased the
urinary fractional sodium and potassium ex-
cretion, with a simultaneous fall in the frac-
tional proximal and post-proximal urinary
sodium excretion (Figure 2).
WPH may influence tubular sodium re-
absorption by a direct action on tubular so-
dium transport or by hemodynamically me-
diated mechanisms involving a reduction in
medullary blood flow. Although neither re-
nal blood flow nor renal vascular resistance
was measured in the present study, the de-
creased glomerular filtration rate, estimated
by CCr, suggested hemodynamic changes in
the glomerular arteriolar vasculature. The
present data support a role for tubular
mechanisms in the conservation of sodium
and water and show an antinatriuretic re-
sponse resulting from a compensatory
natriferric tubular action associated with a
modified glomerular filtration and decreased
arterial blood pressure. Nevertheless, the
persistent decrease in urinary sodium excre-
tion produced after WPH may override the
dramatic reduction in CCr in these rats. Un-
der our experimental conditions, the frac-
tional potassium excretion was also decreased
after WPH administration. Many factors have
been proposed as being important for the
renal excretion of potassium including blood
pH, potential across the luminal membrane,
sodium delivery to the distal tubule, and
urinary flow rate (27). In the present study,
the decreased kaliuresis in WPH-treated rats
may be explained by a remarkable decrease
of sodium delivery to distal tubules as a
consequence of striking potassium reabsorp-
tion before distal nephron segments.
The precise mechanism underlying the
reduction in SBP caused by WPH in SHR is
unknown. The long-term control of arterial
pressure is dominated by renal control of the
fluid and electrolyte balance (28,29). The
interpretation of the results of urinary so-
dium excretion in adult hypertensive rats is
complicated by the interdependency of renal
salt excretion and increased arterial pres-
sure. Several reports have shown that the
basal rates of ion excretion are similar in
normotensive rats and in SHR with estab-
lished hypertension (28,30,31). However,
when the renal perfusion pressure is reduced
to the range observed in normotensive rats,
the urinary sodium excretion of SHR de-
creases (28). The kidneys of SHR require a
higher arterial pressure than those of normo-
tensive rats to excrete the same amount of
salt under basal conditions. The present data
are consistent with this view. The decrease
in SBP in SHR after the administration of
WPH (Figure 2) was associated with a rise in
proximal and post-proximal sodium reab-
sorption despite a supposed fall in in vitro
ACE activity (Figure 1).
The doses of hydrolysate used here pro-
duced responses similar to those observed
by Fujita and Yoshikawa (32) for a peptide
derived from digested thermolysin of dried
Bonito in hypertensive rats. Sipola et al. (33)
showed that peptides derived from whey
proteins relaxed mesenteric arteries. A simi-
lar relaxation in SHR could explain the hy-
potension seen here after the ip administra-
tion of WPH. WPH obtained by digestion
with alcalase may be a potentially useful
source of peptides for functional foods be-
cause of its ability to inhibit in vitro ACE,
and lower SBP in SHR (Figures 1 and 2).
It was recently shown, for example, that
α-lactorphin (34,35) reduced blood pressure
in SHR and normotensive WKy rats in a
dose-dependent manner following subcuta-
neous administration. However, the arterial
blood pressure-reducing effect was absent
in the presence of naloxone, indicating that
the hypotensive effect was mediated through
the vasodilatory action of binding to opiate
receptors (14). Furthermore, the hypoten-
sive effects of milk protein hydrolysates may
also be due in part to the high levels of
biologically available calcium present in
these products (36). The hypotensive effects
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of high calcium, low fat dairy product diets
have been well documented (37).
The present results provide further in-
sights into the cardiovascular and renal ef-
fects of peptides from whey protein on glo-
bal renal function in non-anesthetized, unre-
strained rats. Further studies are needed to
measure the plasma ACE activity and angio-
tensin II levels in rats during the peak hy-
potensive response. Until these studies are
done, the present findings are only sugges-
tive of a pathway involving ACE inhibition.
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